Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 21, 2005

View Archived Issues

HCV-ABXTL-68 shows antiviral activity in liver transplant recipients

Promising results reported from a phase Ib trial on VX-950 in hepatitis C

Escitalopram reported effective in patients with obsessive-compulsive disorder

A new trial announced on Vytorin in patients with acute coronary syndromes

FG-4592: A selective and potent oral erythropoietic agent from FibroGen

Preclinical data on GSK's new TRPV1 antagonist

BNP-054: oral treatment for hypertension

New data on Novartis' competitive NMDA 1A/2A receptor antagonist

Adherex outlines development plans for chemoenhancer eniluracil

SIGA Technologies presents smallpox drug SIGA-246 to WHO

Hexal launches Labopharm's once-daily tramadol product in Germany

ID Biomedical securityholders vote to approve acquisition by GSK

FDA meets to consider pneumococcal conjugate vaccine approvals

Pancrastatin derivative exhibits potent antitumor activity in vivo but not in vitro

Actelion and UCB replace license agreement for Zavesca

SMP-534 effective in treating diabetic nephropathy in db/db mice

Gene therapy as an adjunct to standard MI treatment

Pharmion withdraws Vidaza MAA

SGN-33 begins phase I study for AML and MDS patients

TMC-125 begins phase III program

ZC-423: A novel PDB dimer with remarkable antitumor efficacy

Corgentech and AlgoRx mail definitive proxy for proposed merger

Tysabri sBLA for MS granted priority review

Eisai resubmits rufinamide NDA

Cubicin recommended for approval in Europe

SERMs described in Council of Scientific and Industrial Research patent

Recent patents disclose new analgesic agents

Recent patents report novel treatment options for respiratory disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...